辉瑞公司Pfizer Inc.（PFE）2022年10-K年度报告「NYSE」（英文版）（114页）.pdf

《辉瑞公司Pfizer Inc.（PFE）2022年10-K年度报告「NYSE」（英文版）（114页）.pdf》由会员分享，可在线阅读，更多相关《辉瑞公司Pfizer Inc.（PFE）2022年10-K年度报告「NYSE」（英文版）（114页）.pdf（114页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2022 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the transition period from to Commission file number 1-3619 PFIZER INC.(Exact name of registrant as specified in its charter)Delaware13-5315170(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification Number)66 Hudson Boulevard East,New York,New York 10001-2192

3、(Address of principal executive offices)(zip code)(212)733-2323(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock,$.05 par valuePFENew York Stock Exchang

4、e1.000%Notes due 2027PFE27New York Stock ExchangeSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file

5、 reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was

6、required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter